BONESUPPORT HOLDING AB (BOEUF)
OTHER OTC:BOEUF
BOEUF Stock Chart & Stats
$20.61
$0.00(0.00%)
At close: 4:00 PM EST
$20.61
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$17.66 - $35.00
Previous CloseN/A
Volume21.00
Average Volume (3M)123.00
Market Cap
$1.50B
Enterprise Value$14.69B
Total Cash (Recent Filing)$455.26M
Total Debt (Recent Filing)$14.10M
Price to Earnings (P/E)78.8
Beta0.23
Next Earnings
Jul 16, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.81
Shares Outstanding65,859,190
10 Day Avg. Volume111
30 Day Avg. Volume123
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market Cap9.77
Enterprise Value/Revenue12.09
Enterprise Value/Gross Profit13.08
Enterprise Value/Ebitda52.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.51
Revenue Forecast (FY)$159.82M
Bulls Say, Bears Say
Bulls Say
High Gross & Operating MarginsSustained very high gross margins and improved operating margins reflect strong unit economics and pricing power for the core bioceramic BVF products. Durable margin structure supports reinvestment and returns even as the company scales, underpinning long-run profitability.
Conservative Balance Sheet & Cash FlowRobust operating cash generation and a sizable cash balance with negligible leverage provide financial flexibility to fund commercial expansion, R&D and absorb shocks. Improved cash conversion since 2024 strengthens the durability of growth investments and lowers refinancing risk.
U.S. Commercial Traction & Reimbursement ProgressStrong, accelerating U.S. sales and a favorable CMS proposed ruling (including potential NTAP) materially improve structural adoption economics in hospitals. Durable U.S. momentum plus reimbursement progress supports sustainable market share gains and broader procedure uptake.
Bears Say
Regulatory Timing Uncertainty (CERAMENT V)Approval timing for CERAMENT V remains uncertain; delays postpone access to a reimbursement-enhancing NTAP and defer revenue and margin benefits. Prolonged regulatory timelines could lengthen payback on commercial investments tied to the V indication.
U.S. Tariff-driven Margin PressureNew tariffs create a structural cost headwind for the large U.S. business segment. Even a modest gross-margin erosion requires higher prices or margin compression, which can impede long-term operating leverage from commercial investments and slow margin improvement.
Historical Earnings/cash VolatilityAlthough cash flow is strong recently, the company has a short history of volatile profitability and negative cash conversion. This raises the risk that cyclical, reimbursement, or execution setbacks could reverse recent improvements and lengthen ROI timelines.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $17.66 and its highest was $35.00 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $1.50B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Jul 16, 2026 which is in 40 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Apr 22, 2026. The company reported $0.087 earnings per share for the quarter, missing the consensus estimate of $0.104 by -$0.017.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.12.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.087 in its last earnings report, missing expectations of $0.104. Following the earnings report the stock price went down -0.717%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational picture: strong underlying demand and significant constant-currency revenue growth (notably in the U.S. for CERAMENT G), high gross margins, solid adjusted profitability and robust cash generation. Strategic progress was highlighted by clinical publications, first sales in India, early spine activity, and a favorable CMS proposed ruling that could materially improve reimbursement. Offsetting risks include material currency translation headwinds that reduced reported growth, a tariff-driven margin headwind in the U.S., higher short‑term commercial and incentive costs that will press margins while investments ramp, early-stage/soft BVF spine revenues and timing uncertainty around the CERAMENT V De Novo approval. On balance, the positives (strong growth momentum, cash generation, margin levels, reimbursement progress) materially outweigh the challenges.View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.60% Mutual Funds
― Other Institutional Investors
86.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---